Trinity Biotech Revenue vs. Number Of Shares Shorted
| TRIB Stock | USD 0.79 0.09 10.23% |
Total Revenue | First Reported 1993-03-31 | Previous Quarter 15.8 M | Current Value 15.2 M | Quarterly Volatility 10.2 M |
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Gross Profit Margin | 0.33 | 0.3422 |
|
|
For Trinity Biotech profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Trinity Biotech to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Trinity Biotech plc utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Trinity Biotech's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Trinity Biotech plc over time as well as its relative position and ranking within its peers.
Trinity |
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Trinity Biotech. If investors know Trinity will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Trinity Biotech listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.77) | Earnings Share (2.25) | Revenue Per Share 6.968 | Quarterly Revenue Growth 0.14 | Return On Assets (0.1) |
The market value of Trinity Biotech plc is measured differently than its book value, which is the value of Trinity that is recorded on the company's balance sheet. Investors also form their own opinion of Trinity Biotech's value that differs from its market value or its book value, called intrinsic value, which is Trinity Biotech's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Trinity Biotech's market value can be influenced by many factors that don't directly affect Trinity Biotech's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Trinity Biotech's value and its price as these two are different measures arrived at by different means. Investors typically determine if Trinity Biotech is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Trinity Biotech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Trinity Biotech plc Number Of Shares Shorted vs. Revenue Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Trinity Biotech's current stock value. Our valuation model uses many indicators to compare Trinity Biotech value to that of its competitors to determine the firm's financial worth. Trinity Biotech plc is rated below average in revenue category among its peers. It also is rated below average in number of shares shorted category among its peers . The ratio of Revenue to Number Of Shares Shorted for Trinity Biotech plc is about 738.62 . At present, Trinity Biotech's Total Revenue is projected to increase significantly based on the last few years of reporting. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Trinity Biotech's earnings, one of the primary drivers of an investment's value.Trinity Revenue vs. Competition
Trinity Biotech plc is rated below average in revenue category among its peers. Market size based on revenue of Health Care industry is at this time estimated at about 34.63 Billion. Trinity Biotech adds roughly 56.83 Million in revenue claiming only tiny portion of equities under Health Care industry.
Trinity Number Of Shares Shorted vs. Revenue
Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Trinity Biotech |
| = | 56.83 M |
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
Number of Shares Shorted is the total amount of shares that are currently sold short by investors. When a stock is sold short, the short seller assumes the responsibility of repurchasing the stock at a lower price. The speculator will make money if the stock goes down in price or will experience a loss if the stock price goes up.
Trinity Biotech |
| = | 76.94 K |
If a large number of investors decide to short sell an equity instrument within a small period of time, their combined action can significantly affect the price of the stock.
Trinity Number Of Shares Shorted Comparison
Trinity Biotech is currently under evaluation in number of shares shorted category among its peers.
Trinity Biotech Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Trinity Biotech, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Trinity Biotech will eventually generate negative long term returns. The profitability progress is the general direction of Trinity Biotech's change in net profit over the period of time. It can combine multiple indicators of Trinity Biotech, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Accumulated Other Comprehensive Income | 1 M | 1.1 M | |
| Operating Income | -27 M | -25.7 M | |
| Income Before Tax | -36.9 M | -35.1 M | |
| Total Other Income Expense Net | -9.9 M | -9.4 M | |
| Net Loss | -24 M | -22.8 M | |
| Income Tax Expense | -59 K | -56 K | |
| Net Income Applicable To Common Shares | 787.5 K | 826.9 K | |
| Net Loss | -36.9 M | -35 M | |
| Net Interest Income | -9.9 M | -10.4 M | |
| Change To Netincome | 14.7 M | 14 M | |
| Net Loss | (3.14) | (2.98) | |
| Income Quality | 0.48 | 0.82 | |
| Net Income Per E B T | 0.65 | 0.68 |
Trinity Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Trinity Biotech. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Trinity Biotech position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Trinity Biotech's important profitability drivers and their relationship over time.
Use Trinity Biotech in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Trinity Biotech position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Trinity Biotech will appreciate offsetting losses from the drop in the long position's value.Trinity Biotech Pair Trading
Trinity Biotech plc Pair Trading Analysis
The ability to find closely correlated positions to Trinity Biotech could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Trinity Biotech when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Trinity Biotech - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Trinity Biotech plc to buy it.
The correlation of Trinity Biotech is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Trinity Biotech moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Trinity Biotech plc moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Trinity Biotech can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Trinity Biotech position
In addition to having Trinity Biotech in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Heavy Metals Thematic Idea Now
Heavy Metals
Companies involved in mining, production, and distribution of various industrial metals and minerals. The Heavy Metals theme has 37 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Heavy Metals Theme or any other thematic opportunities.
| View All Next | Launch |
Check out World Market Map. You can also try the Sign In To Macroaxis module to sign in to explore Macroaxis' wealth optimization platform and fintech modules.
To fully project Trinity Biotech's future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Trinity Biotech plc at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Trinity Biotech's income statement, its balance sheet, and the statement of cash flows.